Keywords: |
cancer chemotherapy; clinical article; aged; squamous cell carcinoma; carcinoma, squamous cell; drug efficacy; methotrexate; nephrotoxicity; phase 2 clinical trial; mucosa inflammation; vomiting; gastrointestinal toxicity; kidney; drug therapy; esophagus cancer; adverse drug reaction; esophagus; therapy; clinical trials; esophageal neoplasms; intravenous drug administration; hematologic diseases; middle age; bone marrow depression; drug evaluation; intoxication; dichloromethotrexate; human; priority journal; support, u.s. gov't, p.h.s.; nephrogenic diabetes insipidus; blood and hemopoietic system
|